Diprolene cream in the treatment of severe or resistant corticosteroid-responsive dermatoses.
In a 2-week open study Diprolene Cream was administered to fifty patients with severe or resistant psoriasis, atopic dermatitis or other corticosteroid-responsive dermatoses. Patients applied 3.5 grams of medication twice daily. Efficacy and safety of this preparation were evaluated in forty-seven and fifty patients, respectively. By the third treatment day, therapeutic response was observed in forty-three of forty-seven (91%) evaluable patients. By treatment Day 14, an 83% decrease in the mean total severity score of signs and symptoms was observed in twenty-two psoriatic patients. Similarly, a 91% reduction in the mean total severity score of signs and symptoms was observed in the twenty-five patients with other severe or resistant corticosteroid-responsive dermatoses. Transient burning was reported by twenty-five patients, one of whom also developed laminar scaling. Therapy was not discontinued in any of these patients, and none required treatment. Morning plasma cortisol levels remained within normal limits during and after therapy.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone